A phase II evaluation of pemetrexed [Alimta; LY231514; IND 40061] in the treatment of recurrent or persistent endometrial carcinoma.

Trial Profile

A phase II evaluation of pemetrexed [Alimta; LY231514; IND 40061] in the treatment of recurrent or persistent endometrial carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2014

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Sep 2008 Checked against clinicaltrials.gov record: added patient number and end date.
    • 30 Sep 2008 Checked against clinicaltrials.gov record: added patient number and end date.
    • 30 Sep 2008 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top